Selumetinib in Japanese pediatric patients with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas: An open-label, phase I study.
Souichi SuenobuKeita TerashimaMasaharu AkiyamaTomoyo OguriAsako WatanabeMasatoshi SugenoMitsuo HigashimoriKaren SoYoshihiro NishidaPublished in: Neuro-oncology advances (2023)
selumetinib twice daily was well tolerated with a manageable safety profile in Japanese children with NF1 and symptomatic, inoperable PN.